Moderna, Inc. (NASDAQ:MRNA) is one of the stocks Jim Cramer was recently asked about. Noting that the company is working on a cancer vaccination, a caller asked if they should invest in the stock. Cramer replied: Well, I gotta tell you, this is something that they did promise a long time ago, and I hope that it’s for real… I do say that we have to wait and see. Why? Because the stock’s up so much, 54% for the year. I just want to know how certain things really are. Photo by Ian Hutchinson on Unsplash ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 11 Best Stocks to Buy for Investment. On January 11, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) unveiled its new five-year strategy, ‘Alnylam 2030.’ The company shared its plans to scale operations, focus on durable leadership in transthyretin (TTR) amyloidosis, and deliver sustained, profitable growth. Alnylam Pharmaceuticals Projects 2026 Revenue Around $5.3 Billion as It Focuses on a New Five-Year Strategy Alnylam Pharmaceuticals is targeting ...

Repertoire Immune Medicines entered a strategic collaboration on Thursday with Eli Lilly and Co. (NYSE:LLY) to develop tolerizing therapies for multiple autoimmune diseases. • Eli Lilly and Co stock is showing positive momentum. Where are LLY shares going?Repertoire Immune is a biotechnology company focused on the discovery and development of programmable T cell-targeted immune medicines.Under the terms of the agreement, Repertoire will receive an upfront payment of $85 million and up to an additional $1.84 ...

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, with Harmony Biosciences Holdings, Inc. (HRMY) identified as a strong candidate due to its favorable growth metrics and Zacks Rank [2][10]. Group 1: Earnings Growth - Harmony Biosciences has a historical EPS growth rate of 13.1%, but projected EPS growth for this year is significantly higher at 26.7%, surpassing the industry average of 13% [4]. - Double-digit earnings growth is a key indicator for growth investors, suggesting strong future prospects and potential stock price increases [3]. Group 2: Cash Flow Growth - The company currently exhibits a year-over-year cash flow growth of 10%, which is notably higher than the industry average of -4.5% [5]. - Over the past 3-5 years, Harmony Biosciences has achieved an annualized cash flow growth rate of 25.7%, compared to the industry average of 4.1% [6]. Group 3: Earnings Estimate Revisions - Recent upward revisions in current-year earnings estimates for Harmony Biosciences indicate a positive trend, with the Zacks Consensus Estimate increasing by 7.5% over the past month [8]. - The correlation between earnings estimate revisions and stock price movements supports the potential for near-term price appreciation [7]. Group 4: Overall Assessment - Harmony Biosciences has achieved a Zacks Rank of 1 (Strong Buy) and a Growth Score of B, indicating its potential as an outperformer and a solid choice for growth investors [10].

Amgen Inc. (NASDAQ:AMGN) is included among the 12 Best Dow Jones Dividend Stocks to Buy According to Hedge Funds. UBS Raises Amgen (AMGN) Target as Pharma and Biotech Setup Improves On January 26, UBS lifted its price target on Amgen Inc. (NASDAQ:AMGN) to $390 from $380 and kept a Buy rating on the stock. The call reflects a more constructive view on the broader US pharma and biotech space. UBS expects the group to hold up well this year. Valuations are still appealing, investor positioning remains light ...

New York, New York--(Newsfile Corp. - January 29, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into REGENXBIO Inc. ("REGENXBIO Inc.") (NASDAQ: RGNX) concerning potential violations of the federal securities laws.On January 28, 2026, Regenxbio disclosed via Form 8-K that the FDA placed clinical holds on its RGX-111 and RGX-121 programs following the identification of a tumor in a trial participant. The disclosure prompted a 30-35% decline in the company's share price.SE ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores. What are ...

Key Takeaways UNH shares rose 4% post mixed Q4 results, with EPS beating estimates and revenues missing expectations.UnitedHealth expects a 2026 medical care ratio near 88.8%, reflecting improved cost control versus last year.UnitedHealth projects a 21% cut in 2026 Medicaid membership, raising margin concerns. Shares of UnitedHealth Group Incorporated (UNH) rose 4% during the last trading session at the bourses, following its mixed fourth-quarter 2025 results on Jan. 27, 2026. Higher-than-expected operating ...

CytoMed Therapeutics (GDTC) issued a statement to address recent statements containing “inaccurate and misleading” claims regarding the Company’s research programs, clinical progress, and operations.The company said, ” CytoMed categorically rejects such claims which have no basis. Certain statements circulating publicly mis-characterize the Company’s scientific focus, development status, and regulatory standing. Please refer to recent announcements by the Company on our progress. CytoMed’s research is focu ...

Core Viewpoint - Regenxbio (RGNX) experienced a significant premarket selloff of approximately 30% following the FDA's announcement of a clinical hold on RGX-111 for Hurler syndrome and RGX-121 for Hunter syndrome, indicating a high level of surprise in the market regarding this news [1] Group 1 - Leerink considers the market reaction to be an "overreaction," suggesting that the financial impact of the Hunter and Hurler studies on the overall value of Regenxbio shares is modest [1] - The analyst views the current share price as a buying opportunity, maintaining an Outperform rating on Regenxbio shares [1]